Dechert Advises Emmes on Acquisition of VaxTRIALS

Dechert LLP advised Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, on its acquisition of VaxTRIALS.

Headquartered in Panama City, Panama, VaxTRIALS has more than 160 staff members managing and monitoring vaccine clinical trial activities throughout Latin America. These staff members have supported clinical trials aimed at preventing diseases such as influenza, dengue, chikungunya, hepatitis A, meningitis, norovirus, herpes zoster, pertussis, respiratory syncytial virus (RSV), polio, and COVID-19.

VaxTRIALS’ vaccine-related clinical trials have been conducted in 11 Latin American countries, as well as the Philippines.

This acquisition with VaxTRIALS’ will extend Emmes’ global reach to Latin America, a rapidly growing region for clinical trials. VaxTRIALS will also bring new biopharmaceutical and public-private partnership clients to Emmes, further strengthening its research in vaccines and infectious diseases.

The Dechert team advising Emmes included corporate partner Michael Darby and associate Veronica Casellas Santana; employee benefits partner Kevin Kay; and global tax partner David Passey.

About Dechert

Dechert is a global law firm that advises asset managers, financial institutions and corporations on issues critical to managing their business and their capital – from high-stakes litigation to complex transactions and regulatory matters. We answer questions that seem unsolvable, develop deal structures that are new to the market and protect clients’ rights in extreme situations. Our 1,000+ lawyers across 21 offices globally focus on the financial services, private equity, private credit, real estate, life sciences and technology sectors.